Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 10;6(5):e586.
doi: 10.1212/NXI.0000000000000586. Print 2019 Sep.

Randomized, Controlled Crossover Study of IVIg for Demyelinating Polyneuropathy and Diabetes

Affiliations
Free PMC article

Randomized, Controlled Crossover Study of IVIg for Demyelinating Polyneuropathy and Diabetes

Ari Breiner et al. Neurol Neuroimmunol Neuroinflamm. .
Free PMC article

Abstract

Objective: To determine whether IV immunoglobulin (IVIg) is more effective than placebo at reducing disability in patients with diabetes and demyelinating polyneuropathy features.

Methods: This is a double-blinded, single-center, randomized, controlled crossover trial of IVIg treatment vs placebo. The primary outcome measure was the mean change in Overall Neuropathy Limitation Scale (ONLS) scores during the IVIg phasecompared with the placebo phase. Secondary outcomes include changes in the Rasch-built Overall Disability Scale, Medical Research Council sum scores, grip strength, electrophysiologic measurements, quality of life, and adverse effects.

Results: Twenty-five subjects were recruited between March 2015 and April 2017. The mean change in ONLS scores was -0.2 points during the IVIg phase and 0.0 points during the placebo phase (p = 0.23). Secondary outcomes did not show significant differences between IVIg and placebo.

Conclusions: IVIg did not reduce disability, improve strength, or quality of life in patients with demyelinating polyneuropathy features and diabetes after 3 months of treatment in comparison with placebo. Therefore, careful consideration of the primary diagnosis is required before immunomodulatory therapy.

Classification of evidence: This study provides Class I evidence that for patients with diabetes and demyelinating polyneuropathy features, IVIg did not significantly reduce disability.

Figures

Figure 1
Figure 1. Study procedures
IVIG = IV immunoglobulin.
Figure 2
Figure 2. Consort diagram
IVIg = IV immunoglobulin.

Similar articles

See all similar articles

Cited by 1 article

  • Spectrum of diabetic neuropathies.
    Sasaki H, Kawamura N, Dyck PJ, Dyck PJB, Kihara M, Low PA. Sasaki H, et al. Diabetol Int. 2020 Jan 8;11(2):87-96. doi: 10.1007/s13340-019-00424-7. eCollection 2020 Apr. Diabetol Int. 2020. PMID: 32206478 Review.

References

    1. Köller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005;352:1343–1356. - PubMed
    1. Brannagan TH., III Current diagnosis of CIDP: the need for biomarkers. J Peripher nervous Syst 2011;16(suppl 1):3–13. - PubMed
    1. Van den Bergh PY, Rajabally YA. Chronic inflammatory demyelinating polyradiculoneuropathy. Presse Med 2013;42:e203–e215. - PubMed
    1. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838–845. - PubMed
    1. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996;119(pt 4):1067–1077. - PubMed

Publication types

Feedback